Avid Bioservices Inc (CDMO)

[senrex]

Jazz

Thank you again for all your scientific research. I read everything you post -- but do not always understand all of it --though your underlining of the most pertinent aspects of the text is always helpful.

The BUNNY's comments, however, have disturbed me. Particularly distracting is the following statement: "It may be, however, that Bavi is not the best antibody to implement the basic science. Management has given some hints in that direction, with its refusal to provide the AASLD data to shareholders, its general reduction of Bavi’s scope...."

This articulates some of my fury at the past two quarterly conferences. In my good moments, I remind myself that with very specific trials going on, some of the past references to Bavi widespread potential may be irrelevant till the first data comes in. But, given that hope, can you (or anyone) offer any good reason why management didn't share the AASLD data with us?

TIA.

Sean